Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical Breast Cancer

• Publication date

  2009-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3816/CBC.2009.n.040PMID 19933079
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial.

  2009cited by this paper
• Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum‐resistant ovarian cancer and primary peritoneal carcinomatosis

  2008cited by this paper
• Phase 3 study comparing the use of docetaxel on an every‐3‐week versus weekly schedule in the treatment of metastatic breast cancer

  2008cited by this paper
• Prediction of survival in patients with epithelial ovarian cancer based on the timing and rate of normalization of CA125 levels during primary chemotherapy

  2007cited by this paper
• Irinotecan, Carboplatin, and Imatinib in Untreated Extensive-Stage Small-Cell Lung Cancer: A Phase II Trial of the Minnie Pearl Cancer Research Network

  2007cited by this paper
• Evaluation of imatinib mesylate (IM) in patients with large volume gastrointestinal stromal tumors (GISTs)

  2007cited by this paper
• Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.

  2007cited by this paper
• Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.

  2005cited by this paper
• Bevacizumab, erlotinib, and imatinib in the treatment of patients (pts) with advanced renal cell carcinoma (RCC): A Minnie Pearl Cancer Research Network phase I/II trial

  2005cited by this paper
• Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.

  2003cited by this paper
• Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

  2002cited by this paper
• Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.

  2002cited by this paper
• Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.

  2002cited by this paper
• Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

  2002cited by this paper
• Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors.

  2001cited by this paper
• Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial.

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Docetaxel administered on a weekly basis for metastatic breast cancer.

  2000cited by this paper
• Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• Breast cancer, molecular genetics, pathogenesis and therapeutics

  2000cited by this paper
• The Role of Fibroblast Growth Factors in Breast Cancer Pathogenesis and Progression

  1999cited by this paper
• The Insulin-Like Growth Factor Network and Breast Cancer

  1999cited by this paper
• WNT Genes and Breast Cancer

  1999cited by this paper
• Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer.

  1996cited by this paper
• Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group.

  1996cited by this paper
• Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines.

  1987cited by this paper
• Treatment of advanced renal cell carcinoma.

  1982cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• In situ mapping of activated PDGFRβ defines a prognostic discrepancy between histological subtypes of NSCLC

  2026cites this paper
• PPARγ antagonism as a new tool for preventing or overcoming endocrine resistance in luminal A breast cancers.

  2024cites this paper
• 68Ga‐labeled, imatinib encapsulated, theranostic liposomes: Formulation, characterization, and in vitro evaluation of anticancer activity

  2023cites this paper
• Stromal CCL2 Signaling Promotes Mammary Tumor Fibrosis through Recruitment of Myeloid-Lineage Cells

  2020cites this paper
• Mechanisms of Taxane Resistance

  2020cites this paper
• Dual Mechanisms of LYN Kinase Dysregulation Drive Aggressive Behavior in Breast Cancer Cells

  2018cites this paper
• A Case of Complete Resection of Locally Advanced Breast Cancer Resistant to Preoperative Chemotherapy by Radical Mastectomy, with Thoracic Wall Resection and Latissimus Dorsi Myocutaneous Flap Reconstruction

  2017cites this paper
• Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer*

  2016cites this paper
• Vitamin D Analogs Potentiate the Antitumor Effect of Imatinib Mesylate in a Human A549 Lung Tumor Model

  2015cites this paper
• Molecular and Cellular Mechanisms of Action of Tumour Suppressor GAS5 LncRNA

  2015cites this paper
• Malignant stroma increases luminal breast cancer cell proliferation and angiogenesis through platelet-derived growth factor signaling

  2014cites this paper
• Final Safety and Efficacy Analysis of a Phase I/II Trial with Imatinib and Vinorelbine for Patients with Metastatic Breast Cancer

  2014cites this paper
• A phosphotyrosine switch determines the antitumor activity of ERβ.

  2014cites this paper
• Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients

  2013cites this paper
• Bisdemethoxycurcumin inhibits PDGF-induced vascular smooth muscle cell motility and proliferation.

  2013cites this paper
• Potentiation of anti-cancer treatment by modulators of energy metabolism.

  2013cites this paper
• A phase I trial of imatinib in combination with mFOLFOX6–bevacizumab in patients with advanced colorectal cancer

  2013influential citation
• Soluble KIT correlates with clinical outcome in patients with metastatic breast cancer treated with sunitinib

  2012cites this paper
• A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma.

  2012cites this paper
• The in-vitro antiproliferative effect of PRI-2191 and imatinib applied in combined treatment with cisplatin, idarubicin, or docetaxel on human leukemia cells

  2012cites this paper
• A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer

  2012cites this paper
• Docetaxel combined with targeted therapies in metastatic breast cancer.

  2012cites this paper
• Targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigm.

  2012cites this paper
• Stroÿma-Directed Molecular Targeted Therapy in Gastric Cancer

  2011cites this paper
• Will imatinib compromise reproductive capacity?

  2011cites this paper
• RET in breast cancer: functional and therapeutic implications.

  2011cites this paper
• Phase II Trials of Imatinib Mesylate and Docetaxel in Patients with Metastatic Non-small Cell Lung Cancer and Head and Neck Squamous Cell Carcinoma

  2011cites this paper
• Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer

  2011cites this paper
• Molecular Characterization of c-Abl/c-Src Kinase Inhibitors Targeted against Murine Tumour Progenitor Cells that Express Stem Cell Markers

  2010cites this paper
• - 1In Vitro Effects of Imatinib Mesylate on Radiosensitivity and Chemosensitivity of Breast Cancer Cells

  2010cites this paper
• In vitro effects of imatinib mesylate on radiosensitivity and chemosensitivity of breast cancer cells

  2010cites this paper
• Repository Citation

  year unknowncites this paper